Small Research Grants for Analyses of Data for the Gabriella Miller Kids First Data Resource (R03)
Funding Opportunity ID: 285569 Opportunity Number: PAR-16-348 Opportunity Title: Small Research Grants for Analyses of Data for the Gabriella Miller Kids First Data Resource (R03)Opportunity Category: DiscretionaryOpportunity Category Explanation: Funding Instrument Type: GrantCategory of Funding Activity: EducationHealthIncome Security and Social ServicesCategory Explanation: CFDA Number(s): 93.12193.27393.39493.39593.39993.85393.865Eligible Applicants: State governmentsCounty governmentsCity or township governmentsSpecial district governmentsIndependent school districtsPublic and State controlled institutions of higher educationNative American tribal governments (Federally recognized)Public housing authorities/Indian housing authoritiesNative American tribal organizations (other than Federally recognized tribal governments)Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher educationNonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher educationPrivate institutions of higher educationFor profit organizations other than small businessesSmall businessesOthers (see text field entitled "Additional Information on Eligibility" for clarification)Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible A...
Mosaic-variegated aneuploidy (MVA) syndrome is a rare childhood disorder characterized by biallelic BUBR1, CEP57, or TRIP13 aberrations; increased chromosome missegregation; and a broad spectrum of clinical features, including various cancers, congenital defects, and progeroid pathologies. To investigate the mechanisms underlying this disorder and its phenotypic heterogeneity, we mimicked the BUBR1L1012P mutation in mice (BubR1L1002P) and combined it with 2 other MVA variants, BUBR1X753 and BUBR1H, generating a truncated protein and low amounts of wild-type protein, respectively. Whereas BubR1X753/L1002P and BubR1H/X753 mi...
Only a few months after announcing that it will cease production of this essential medicine for childhood cancers, Teva has announced it will jump back into the market.Medscape Medical News
In 60 - year follow - up, significantly lower lung cancer rates seen for those with childhood BCG vaccination
(Academy of Medical Sciences (UK)) Professor Muzlifah Haniffa from Newcastle University and the Wellcome Sanger Institute* has won the 2019 Foulkes Foundation Medal for her ground-breaking contributions to biomedical science, it was announced today [Tuesday 19 November, 2019]. Professor Haniffa's research achievements include providing a better understanding of the developing human immune system and childhood kidney cancer, mapping the maternal-fetal interface and discovering new immune cells in the skin.
Conclusion: Our data demonstrate that crocins could be a novel promising agent for the improvement of tumor treatment.
This article reviews the application of the precautionary principle during critical periods of growth and development and provides recommendations that may prevent epigenetic changes and reduce the risk for cancer. PMID: 31730600 [PubMed - in process]
ConclusionsThis is the first sun protection accreditation program developed for Spanish schools. Studies are needed to evaluate how this program is received and how it affects students’ sun protection behaviors.ResumenIntroducciónLa exposición solar en la infancia es el principal factor de riesgo para el desarrollo de cáncer de piel en la vida adulta. Las intervenciones basadas en programas y políticas de fotoprotección escolar han demostrado ser las estrategias más eficaces y coste-efectivas para la prevención del cáncer de piel.ObjetivosElaborar un modelo de c...
Teva Pharmaceuticals announced that it will resume production of childhood cancer drug vincristine after a recent shortage.
BOSTON (CBS) — Melanoma is the deadliest form of skin cancer, but a new study published in JAMA Dermatology finds melanoma rates are actually dropping, at least in young people. Melanoma is linked to exposing skin to ultraviolet light (UV), most notably through sunburns during childhood. Researchers looked at data from almost a million cases of invasive melanoma between 2006 and 2015, and found that while the rates ticked up in adults over 40, they dropped 23% among adolescents and adults under 30. They say this suggests that public health efforts to get people to use sun protection and avoid excessive UV exposure is working.
Conclusions: Collaborative efforts to conduct multi-centre trials are needed to further the field of paediatric oncology PT. PMID: 31719724 [PubMed]